Herceptin and Nail abnormalities - a phase IV clinical study of FDA data

Summary:

Nail abnormalities is reported as a side effect among people who take Herceptin (trastuzumab), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Perjeta, and have Breast cancer female.

The phase IV clinical study analyzes which people have Nail abnormalities when taking Herceptin. It is created by eHealthMe based on reports of 41,859 people who have side effects when taking Herceptin from the FDA, and is updated regularly.

What is Herceptin?

Herceptin has active ingredients of trastuzumab. It is often used in breast cancer. eHealthMe is studying from 42,205 Herceptin users. Check the latest studies of Herceptin.

What is Nail abnormalities?

Nail abnormalities (abnormal nail) is found to be associated with 212 drugs and 651 conditions by eHealthMe. Check the latest studies of Nail abnormalities.

On Jul, 05, 2026

41,859 people reported to have side effects when taking Herceptin.
Among them, 74 people (0.18%) have Nail abnormalities.

Could Herceptin cause Nail abnormalities?

Among these 74 people:

How long have people been on Herceptin when they have Nail abnormalities? *

What is the gender of people who have Nail abnormalities when taking Herceptin? *

female: 97.1 %
male: 2.9 %

What is the age of people who have Nail abnormalities when taking Herceptin? *

What are other drugs people take besides Herceptin? *

What are other side effects people have besides Nail abnormalities? *

Joint Pain: 15 people, 20.27%
Diarrhea: 15 people, 20.27%
Neuropathy Peripheral (surface nerve damage): 13 people, 17.57%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 13 people, 17.57%
Oedema Peripheral (superficial swelling): 12 people, 16.22%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 11 people, 14.86%
Conjunctivitis (pink eye): 10 people, 13.51%
Nail Disorder (disease of nail): 10 people, 13.51%
Onychalgia (nail biting): 10 people, 13.51%
Nausea (feeling of having an urge to vomit): 10 people, 13.51%

What are the existing conditions these people have? *

Breast Cancer Female: 4 people, 5.41%
Depression: 3 people, 4.05%
White Blood Cell Count Decreased: 1 person, 1.35%
Stress And Anxiety: 1 person, 1.35%
Nausea (feeling of having an urge to vomit): 1 person, 1.35%
Metastases To Bone (cancer spreads to bone): 1 person, 1.35%
Hypersensitivity: 1 person, 1.35%
Erythrodermic Psoriasis (generalized redness of the skin): 1 person, 1.35%
Cardiac Neoplasm Malignant (a tumour spread from other part of body): 1 person, 1.35%
Breast Cancer Stage Iii: 1 person, 1.35%

* Approximation only. Some reports may have incomplete information.

Do you take Herceptin and have Nail abnormalities?

- Check whether Nail abnormalities is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Herceptin:

Herceptin (42,205 reports)

Browse all side effects of Herceptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nail abnormalities:

Nail abnormalities (212 drugs)

Browse all the conditions that are associated with Nail abnormalities:

Nail abnormalities (651 conditions)

Related publications that referenced our studies

Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .
Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on trastuzumab (the active ingredients of Herceptin) and Herceptin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.